RxDoctor Payments Data

Blessy Jacob, MD

Medical Oncology · Englewood, FLNPI 1851525406

Payments from drug & device makers

$1,232,777in general payments, 2019–2025

Across 732 payments — averaging $1684.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$888K
  • AbbVie$242K
  • Bristol Myers Squibb$64K
  • Pfizer$20K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Epizyme, Inc.$1K
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1,3759%
  • Food & beverage$13,21490%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis56$887,862
AbbVie47$241,647
Bristol Myers Squibb39$64,088
Pfizer40$20,091
E.r. Squibb & Sons, L.L.C.72$8,014
Epizyme, Inc.7$1,343
Merck55$1,023
AstraZeneca(2 entities)41$815
Gilead(2 entities)30$654
Lilly USA, LLC29$624
Daiichi Sankyo Inc.22$578
Johnson & Johnson26$442
Incyte Corporation19$435
Genentech USA, Inc.24$360
Exelixis Inc.19$348
Astellas Pharma US Inc15$290
GSK12$269
Takeda Pharmaceuticals U.S.A., Inc.11$267
Array Biopharma Inc15$260
Genmab U.S., Inc.5$229
Sanofi13$222
Bayer11$195
Acrotech Biopharma Inc.5$179
Jazz Pharmaceuticals Inc.4$173
Puma Biotechnology, Inc.8$164
EMD Serono, Inc.7$133
Seagen Inc.7$128
Dova Pharmaceuticals7$119
Eisai Inc.5$104
Ipsen Biopharmaceuticals, Inc1$102
Beigene USA, Inc.4$101
Sobi, Inc5$96
Pharmaessentia USA Corporation4$93
Sumitomo Pharma America, Inc.5$92
Dendreon Pharmaceuticals LLC3$84
Boehringer Ingelheim3$75
Amgen5$64
Pharmacyclics LLC, An Abbvie Company3$61
Myriad Genetic Laboratories, Inc.2$60
Rigel Pharmaceuticals, Inc.3$56
Stemline Therapeutics Inc.2$51
Myovant Sciences Inc.3$50
Mirati Therapeutics, Inc.2$42
Beone Medicines USA, Inc.2$42
Janssen Scientific Affairs, LLC1$41
Tersera Therapeutics LLC3$40
Immunogen, Inc.2$40
Regeneron Healthcare Solutions, Inc.2$37
Siemens Medical Solutions USA, Inc.2$36
Agios Pharmaceuticals, Inc.2$36
Pharmacosmos Therapeutics Inc.2$35
ADC Therapeutics America, Inc.2$34
Partner Therapeutics, Inc.2$34
Karyopharm Therapeutics Inc.2$31
Recordati_rare_diseases_inc.1$24
Coherus Oncology, Inc.1$24
Fennec Pharmaceuticals, Inc.1$23
Geron Corporation1$23
AVEO Pharmaceuticals, Inc.1$22
Syndax Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,232,777 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$7,369,248
Medicare patients
1,663
Services billed
379,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide59$935,621
ImbruvicaIbrutinib48$669,201
IbrancePalbociclib31$401,068
BrukinsaZanubrutinib35$391,087
TibsovoIvosidenib11$350,332
JakafiRuxolitinib Phosphate13$225,369
XtandiEnzalutamide16$219,736
GilotrifAfatinib Dimaleate12$137,698
YonsaAbiraterone Acet,submicronized12$124,903
EliquisApixaban26$39,258
ZoladexGoserelin Acetate12$10,290
Exemestane12$5,478
Abiraterone Acetate15$5,187
Anastrozole134$2,936
Hydroxyurea31$1,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$64,088$935,62159 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$61$669,20148 claims
PfizerIbrance, Eliquis$20,091$440,32657 claims
Beigene USA, Inc.Brukinsa$101$391,08735 claims
Incyte CorporationJakafi$435$225,36913 claims
Astellas Pharma US IncXtandi$290$219,73616 claims
Boehringer IngelheimGilotrif$75$137,69812 claims
Tersera Therapeutics LLCZoladex$40$10,29012 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$41$5,18715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Englewood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →